Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease.
about
Review. The neurobiology of pathological gambling and drug addiction: an overview and new findingsImpact of Impulse Control Disorders on Sleep-Wake Regulation in Parkinson's DiseaseThe hidden sister of motor fluctuations in Parkinson's disease: A review on nonmotor fluctuations.Novelty seeking behaviour in Parkinson's disease.Targeting impulsivity in Parkinson's disease using atomoxetineFrequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome.Influence of depressive symptoms on dopaminergic treatment of Parkinson's diseaseImpulsive and compulsive behaviors in Parkinson's diseaseTreatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease.Behavioral effects of levodopa.Pramipexole and compulsive masturbationImpulsive behavior and associated clinical variables in Parkinson's disease.A conditioned response as a measure of impulsive-compulsive behaviours in Parkinson's disease.Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET studyDopamine and impulse control disorders in Parkinson's disease.Ventral striatal dopamine synthesis capacity predicts financial extravagance in Parkinson's diseaseDiagnosis and treatment of impulse control disorders in patients with movement disordersImpulsive choice and response in dopamine agonist-related impulse control behaviors.Acetaldehyde and parkinsonism: role of CYP450 2E1.Trait Impulsivity and Anhedonia: Two Gateways for the Development of Impulse Control Disorders in Parkinson's Disease?Reward-learning and the novelty-seeking personality: a between- and within-subjects study of the effects of dopamine agonists on young Parkinson's patients.Multiple modes of impulsivity in Parkinson's disease.Sexual function of women with chronic illness and cancer.Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson's disease.Drug-induced impulse control disorders in Parkinson's disease.Compulsive use of dopamine replacement therapy: a model for stimulant drug addiction?Addiction-like manifestations and Parkinson's disease: a large single center 9-year experience.Dopamine dysregulation syndrome and deep brain stimulation of the subthalamic nucleus in Parkinson's disease.Impulse control disorders in Parkinson's disease: the role of personality and cognitive status.Drug treatments for the neuropsychiatric complications of Parkinson's disease.Cognitive deficits in Parkinson's disease: a cognitive neuroscience perspective.Apathy and Impulse Control Disorders: Yin & Yang of Dopamine Dependent Behaviors.Neuropsychiatric Issues in Parkinson's Disease.Neuropsychiatric manifestations of Parkinson's disease.A neurological perspective on the enhancement debate: Lessons learned from Parkinson's disease.A multidimensional approach to impulsivity in Parkinson's disease: measurement and structural invariance of the UPPS Impulsive Behaviour Scale.Altered striatal circuits underlie characteristic personality traits in Parkinson's disease.The use of carer assisted adherence therapy for people with Parkinson's disease and their carers (CAAT-PARK): study protocol for a randomised controlled trialDopamine-induced nonmotor symptoms of Parkinson's disease.Deletion of alpha-synuclein decreases impulsivity in mice.
P2860
Q24641954-2D674AAC-7FA3-44BD-801F-62FFD1F7C7C6Q26776152-8AD7F370-1895-4C7D-B397-759D5128C5E3Q30248922-B5FB6B2E-2AA2-4055-881A-7217AFF5E1EEQ30466231-7826F3AD-8ABE-4F1E-AE6C-248E3A46B3D2Q33784038-3BB0546B-A52B-4EA3-AB78-932AC3CFCF56Q34034076-B7DFD24B-56E1-41A6-B8A1-FD4A5C41F162Q34242604-184B16E9-4698-468D-90D8-3764D9ED0A63Q34342432-C8373351-323E-4682-B02B-466BAC4D7D39Q34388686-4B79060B-B701-41B5-960B-661B417960D1Q34452922-99260592-38E6-44A1-AFF8-A3760FAE8612Q34620342-948730A2-E39A-43FA-B8CA-2733E3E05006Q34778024-566F67B3-9C87-47C4-8483-A088832EFB4DQ35107051-3ED7DD71-4B91-4EA6-B020-0069EBE9AC05Q36341411-0ACE9180-DCB1-4D9C-A7F0-8E25ED29BF28Q36488497-D0D15716-CED0-4073-8453-B445F6293711Q36641307-92ABB507-7894-42E0-ACC6-F421177E7AB6Q36761848-36CEECAE-DEB0-463C-9260-18CB35B2DBA2Q36914016-3F9EBE54-1217-42EA-870F-96EBD7A052FEQ36946015-7A508348-074A-4184-A7C8-7858469D6C64Q36946063-BE5094B9-C526-438C-9094-A3C834BC5972Q37397116-AAB613B6-B71B-4975-8D0E-08A64B7F3113Q37499687-2E9457C1-DD1F-478F-B099-D67F53556772Q37738879-2685BE6C-0D9B-4F00-B79F-0A2C1B611298Q37855572-FA5C38F3-241F-4524-8082-E9172202465EQ37874193-72585D4E-7A9D-416D-861C-D370681756F5Q37906769-CAF71FB2-FB9D-4941-8855-8B438860FD1EQ37948926-ED265AD9-46B4-4FB4-B11B-8980DC746968Q37963887-B8C294C7-C91F-4555-B3D6-E96BB2DE1F8EQ38005346-AE2D4FA3-905F-4F1F-8A7F-3BD5C77FB60AQ38067142-DB420B37-C1B3-4C49-8CDA-566E404CD302Q38206496-D1FF321D-8F0C-4C7F-918A-9DDE034C98A5Q38419501-6D360F7B-8F45-43D9-9F08-44EFC4193BE7Q38799051-BEAB633C-CC44-41DE-AC58-EF2DA3ED0C27Q38908099-E1B4F9A6-7FB2-47AD-94F9-74448171482DQ38948788-1409923E-7DF4-4EE3-88CA-090EC073F576Q39557865-E524D725-E2F0-4431-92AE-DED125063541Q39661805-84314F80-2296-4235-A0A3-48054122B8B2Q39714311-9817F0DE-B2F8-44E1-B128-F46460365B72Q41835359-FB5C52DA-17F6-4F71-94E2-AA642C73281DQ42151730-23B331AB-8262-4493-9A40-494B60578D4C
P2860
Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Factors influencing susceptibi ...... drug use in Parkinson disease.
@en
Factors influencing susceptibi ...... drug use in Parkinson disease.
@nl
type
label
Factors influencing susceptibi ...... drug use in Parkinson disease.
@en
Factors influencing susceptibi ...... drug use in Parkinson disease.
@nl
prefLabel
Factors influencing susceptibi ...... drug use in Parkinson disease.
@en
Factors influencing susceptibi ...... drug use in Parkinson disease.
@nl
P2093
P1433
P1476
Factors influencing susceptibi ...... drug use in Parkinson disease.
@en
P2093
P304
P356
10.1212/01.WNL.0000184487.72289.F0
P407
P577
2005-11-01T00:00:00Z